Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease.

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Tang, Shengnan en
dc.contributor.author Wang, Aiping en
dc.contributor.author Yan, Xiuju en
dc.contributor.author Chu, Liuxiang en
dc.contributor.author Yang, Xiucheng en
dc.contributor.author Song, Yina en
dc.contributor.author Sun, Kaoxiang en
dc.contributor.author Yu, Xin en
dc.contributor.author Liu, Rongxia en
dc.contributor.author Wu, Zimei en
dc.contributor.author Xue, Peng en
dc.date.accessioned 2020-02-18T01:10:51Z en
dc.date.issued 2019-12 en
dc.identifier.citation Drug delivery 26(1):700-707 Dec 2019 en
dc.identifier.issn 1071-7544 en
dc.identifier.uri http://hdl.handle.net/2292/50100 en
dc.description.abstract Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson's disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug delivery system to achieve maximum therapeutic efficacy and reduce side effects for PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method and evaluated for physicochemical and pharmaceutical properties. In vitro cytotoxicity studies indicated that treatment with dopamine Lf-BNPs has relatively low cytotoxicity in SH-SY5Y and 16HBE cells. Qualitative and quantitative cellular uptake experiments indicated that Lf modification of NPs increased cellular uptake of SH-SY5Y cells and 16HBE cells, and borneol modification can promote the cellular uptake of 16HBE. In vivo pharmacokinetic studies indicated that AUC0-12 h in the rat brain for dopamine Lf-BNPs was significantly higher (p < .05) than that of dopamine nanoparticles. Intranasal administration of dopamine Lf-BNPs effectively alleviated the 6-hydroxydopamine-induced striatum lesion in rats as indicated by the contralateral rotation behavior test and results for striatal monoamine neurotransmitter content detection. Taken together, intranasal administration of dopamine Lf-BNPs may be an effective drug delivery system for Parkinson's disease. en
dc.format.medium Print en
dc.language eng en
dc.relation.ispartofseries Drug delivery en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.rights.uri https://creativecommons.org/licenses/by/4.0/ en
dc.subject Brain en
dc.subject Cells, Cultured en
dc.subject Animals en
dc.subject Rats en
dc.subject Rats, Sprague-Dawley en
dc.subject Parkinson Disease en
dc.subject Dopamine en
dc.subject Lactoferrin en
dc.subject Antiparkinson Agents en
dc.subject Drug Delivery Systems en
dc.subject Administration, Intranasal en
dc.subject Nanoparticles en
dc.subject Camphanes en
dc.title Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease. en
dc.type Journal Article en
dc.identifier.doi 10.1080/10717544.2019.1636420 en
pubs.issue 1 en
pubs.begin-page 700 en
pubs.volume 26 en
dc.rights.holder Copyright: The authors en
pubs.end-page 707 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Journal Article en
pubs.elements-id 777182 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Pharmacy en
dc.identifier.eissn 1521-0464 en
pubs.record-created-at-source-date 2019-07-11 en
pubs.dimensions-id 31290705 en


Full text options

Find Full text

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/ Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/

Share

Search ResearchSpace


Advanced Search

Browse